Enroxil Flavour Tablets 150 mg

Main information

  • Trade name:
  • Enroxil Flavour Tablets 150 mg
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Enroxil Flavour Tablets 150 mg
    Germany
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • enrofloxacin
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0255/003
  • Authorization date:
  • 12-10-2009
  • EU code:
  • UK/V/0255/003
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:December2009

AN:01104/2009

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

EnroxilFlavour150mgTabletsfordogs

EnroxFlavour150mgTabletsfordogs(UnitedKingdom,Austria,Belgium,

Germany,Denmark,Greece,Ireland,Italy,Luxembourg,Netherlands)

EnroxSabor150mgTabletsfordogs(Spain,Portugal)

EnroxilFlavour150mgTabletsfordogs(Bulgaria,CzechRepublic,Hungary,

Lithuania,Latvia,Poland,Romania,Slovenia,Slovakia)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Activesubstance:

Eachtabletcontains:

Enrofloxacin150mg

Excipients:Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Tablet.

Roundslightlybiconvex,creamtolightbrownishtabletswithpossiblevisible

whiteordarkerspots,onesidescoredandbevel-edged.

Thetabletscanbedividedintoequalhalves

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogs.

4.2 Indicationsforuse,specifyingthetargetspecies

Theproductisforuseindogsinthetreatmentofbacterialinfectionsofthe

alimentary,respiratoryandurogenitaltracts,skin,secondarywoundinfections

andotitisexternawhereclinicalexperience,supportedwherepossibleby

sensitivitytestingofthecausalorganism,indicatesenrofloxacinasthedrugof

choice.

4.3 Contraindications

Donotuseindogslessthan1yearofageorinexceptionallylargebreedsof

dogwithalongergrowthperiodlessthan18monthsofage,asarticular

cartilagemaybeaffectedduringtheperiodofrapidgrowth.

Donotuseincaseofhypersensitivitytotheactivesubstanceortoanyofthe

excipients.

Donotuseindogshavingseizuredisorders,sinceenrofloxacinmaycause

CNSstimulation.

Revised:December2009

AN:01104/2009

4.4 Specialwarningsforeachtargetspecies

Pleaseseepoint4.3.

4.5 Specialprecautionsforuse

i) Specialprecautionsforuseinanimals

Fluoroquinolonesshouldbereservedforthetreatmentofclinicalconditions

whichhaverespondedpoorly,orareexpectedtorespondpoorlytoother

classesofantimicrobials.

Wheneverpossible,useoffluoroquinolonesshouldbebasedonsusceptibility

testing.UseoftheproductdeviatingfromtheinstructionsgivenintheSPC

mayincreasetheprevalenceofbacteriaresistanttothefluoroquinolonesand

maydecreasetheeffectivenessoftreatmentwithotherquinolonesduetothe

potentialforcross-resistance.

Officialandlocalantimicrobialpoliciesshouldbetakenintoaccountwhenthe

productisused.

Theproductshouldnotbeusedforprophylaxis.

Donotexceedtherecommendeddosage.

Usetheproductwithcautionindogswithsevererenalorhepaticimpairment.

ii) Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Washhandsafteruse.

Incaseofcontactwiththeeyes,washwithplentyofcleanwater.

Incaseofaccidentalingestion,seekmedicaladviceimmediatelyandshow

thepackageleaflettothephysician.

Peoplewithknownhypersensitivitytofluoroquinolonesshouldavoidcontact

withtheproduct.

4.6Adversereactions(frequencyandseriousness)

Duringtheperiodofrapidgrowth,enrofloxacinmayaffectarticularcartilage

development.

Inrarecasesvomitingandanorexiaareobserved

4.7Useduringpregnancy,lactationorlay

Useonlyaccordingtothebenefit:riskassessmentbytheveterinarysurgeon.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Donotcombinewithtetracyclines,phenicolsormacrolidesbecauseof

potentialantagonisticeffects.

Concurrentadministrationoffluoroquinolonesmayincreasetheactionoforal

anticoagulants.

Revised:December2009

AN:01104/2009

Donotcombinewiththeophyllineasthiscouldleadtoaprolongedelimination

ofthissubstance.

Concurrentadministrationofmagnesiumoraluminumcontainingsubstances

maybefollowedbyretardedabsorptionofenrofloxacin.

4.9Amountstobeadministeredandadministrationroute

Donotexceedtherecommendeddose.Thedosagerateofenrofloxacinis5

mg/kggivenorallyoncedailyorasadivideddosetwicedailyfor5to10days

withorwithoutfood.

Thedurationoftreatmentindogsmaybeextendeddependingontheclinical

responseandthejudgementoftheresponsibleveterinarysurgeon.

Toensureacorrectdosagebodyweightshouldbedeterminedasaccurately

aspossibletoavoidunderdosing.

Thedailydoseisachievedasfollows:

Largedogs:onetabletper30kgbodyweight.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Inaccidentaloverdosevomiting,diarrhoeaandCNS/behaviouralchanges

mayoccur.Thereisnoantidoteandtreatmentshouldbesymptomatic.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Enrofloxacinisasynthetic,broadspectrum

antimicrobialsubstance,belongingtothefluoroquinolonegroupofantibiotics.

ATCvetcode:QJ01MA90

5.1 Pharmacodynamicproperties

EnrofloxacinisbactericidalinactionwithactivityagainstGrampositiveand

Gramnegativebacteriaandmycoplasmas.Themechanismofactionofthe

quinolonesisuniqueamongantimicrobials –theyactprimarilytoinhibit

bacterialDNAgyrase,anenzymeresponsibleforcontrollingthesupercoiling

ofbacterialDNAduringreplication.Resealingofthedoublestandardhelixis

inhibitedresultinginirreversibledegradationofthechromosomalDNA.The

fluoroquinolonesalsopossessactivityagainstbacteriainthestationaryphase

byanalterationofthepermeabilityoftheoutermembranephospholipidcell

wall.

Bacterialresistancetofluoroquinolonesmostcommonlyoccursbyalterationof

thetarget,DNA-gyrase,viamutation.Lesscommonlymutationoccursatthe

topoisomerase-IVtarget.Othermechanismsofresistanceoccurwhen

bacteriadecreasetheabilityofthedrugtoenterthecellorincreaseactive

transportoutofthecell.Resistanceisusuallychromosomallydevelopedand,

Revised:December2009

AN:01104/2009

therefore,remainsafterantimicrobialtherapyends.Cross-resistanceof

enrofloxacinwithotherfluoroquinolonescanoccur.Changesinlevelsof

resistancetofluoroquinolonesovertimebyCampylobacterandSalmonella

speciesarebeingmonitoredbecauseoftheirpossibleimpactonhuman

health.

5.2 Pharmacokineticparticulars

Thepharmacokineticsofenrofloxacinindogsissuchthatoralandparenteral

administrationleadstosimilarserumlevels.

Enrofloxacinisrapidlyabsorbedafteroral,intramuscularandsubcutaneous

administration.

Inthestudyconductedindogsthedoseofenrofloxacinadministeredwas4.91

mg/kg.Themaximalplasmaconcentrationwas1179.94±260,83ng/mL,Tmax

was1.57±0.62h,halflife3,78h(harmonicmean)andAUC

tot value

4037±1155.82ngh/mL.

Approximately40%oftheoralorintravenousenrofloxacindoseadministered

indogsismetabolisedtociprofloxacin.

Themeanmaximalconcentrationforciprofloxacinreached491.99±57.95

ng/mL,tmax1.79±2.6handtheapparentterminalhalflifewas5.10h

(harmonicmean).ThemeanAUC

tot forciprofloxacinwas3737.21±562.65

ngh/mL.Enrofloxacinpossessesahighdistributionvolume.Tissuelevels2-3

timeshigherthanthatfoundintheserum,havebeendemonstratedin

laboratoryanimalsandtargetspecies.Organsinwhichhighlevelscanbe

expectedarethelungs,liver,kidney,skin,boneandlymphaticsystem.

Enrofloxacinalsodistributesintothecerebrospinalfluid,theaqueoushumour

andthefoetusinpregnantanimals.

Theeliminationofenrofloxacinisrenal,primarilythroughglomerularfiltration

andtubularsecretion.

6. PHARMACEUTICALPARTICULARS

6.1.Listofexcipients

Mannitol

Maizestarch

Sodiumstarchglycolate(typeA)

Meatflavour10022

Sodiumlaurilsulphate

Basicbutylatedmethacrylatecopolymer

Dibutylsebacate

Croscarmellosesodium

Silica,colloidalanhydrous

Talc

Magnesiumstearate

6.2Incompatibilities

Noneknown.

Revised:December2009

AN:01104/2009

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years

Returnanyhalvedtablettotheopenedstrip-packandusewithin24hours.

6.4.Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorage

conditions.

6.5Natureandcompositionofimmediatepackaging

Polyamide/Aluminium/Polyvinylchloridefilm(OPA/Al/PVC),heatsealedwith

aluminiumfoilcontaining10tablets/blister.Eachcardboardcartoncontains

10blisterpacks.

Polyamide/Aluminium/Polyvinylchloridefilm(OPA/Al/PVC),heatsealedwith

aluminiumfoilcontaining10tablets/blister.Eachcardboardcartoncontains

1blisterpacks.

Notallpacksizesmaybemarketed

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

KRKA,d.d.,Novomesto

Šmarješkacesta6

8501Novomesto

Slovenia

Telephonenumber:073312111

Faxnumber:073321537

Email:info@krka.biz

8. MARKETINGAUTHORISATIONNUMBER

Vm 01656/4009

9. DATEOFFIRSTAUTHORISATION

18June2009

10. DATEOFREVISIONOFTHETEXT

December2009

30-10-2018

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP  75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

ScieGen Pharmaceuticals, Inc. is voluntarily recalling listed lots, within expiry, of Irbesartan Tablets, USP 75 mg, 150 mg, and 300 mg dosage forms to the consumer level. These products are being recalled due to the presence of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Irbesartan, USP manufactured by Aurobindo Pharma Limited. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a...

FDA - U.S. Food and Drug Administration

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

3-8-2018

Scientific guideline:  Vismodegib hard capsule 150 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Vismodegib hard capsule 150 mg product-specific bioequivalence guidance, adopted

Vismodegib hard capsule 150 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

31-7-2018

Public Notification: Boss Rhino 15000 contains hidden drug ingredient

Public Notification: Boss Rhino 15000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Boss Rhino 15000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

19-7-2018

K9 Natural Ltd recalls K9 Natural Frozen Chicken Feast Raw Pet Food 11lb bags

K9 Natural Ltd recalls K9 Natural Frozen Chicken Feast Raw Pet Food 11lb bags

K9 Natural Ltd is voluntarily recalling K9 Natural Frozen Chicken Feast 11lb bags, batch number #150517, that were imported into the Canadian market in July 2017 because they have the potential to be contaminated with Listeria monocytogenes. No other K9 Natural products are affected in Canada.

Health Canada

1-8-2017

Withdrawal of one more batch of counterfeit packs of the schizophrenia medicine Xeplion 150 mg

Withdrawal of one more batch of counterfeit packs of the schizophrenia medicine Xeplion 150 mg

German and Danish parallel importers and the Danish Medicines Agency are now withdrawing the fourth batch of Xeplion 150 mg from wholesale distributors, hospitals and pharmacies, because the batch contains counterfeit packs.

Danish Medicines Agency

27-7-2017

Counterfeit packs of the schizophrenia medicine Xeplion 150 mg

Counterfeit packs of the schizophrenia medicine Xeplion 150 mg

One German and several Danish parallel importers and the Danish Medicines Agency have withdrawn several batches of Xeplion 150 mg from wholesale distributors, hospitals and pharmacies, because the batches contained counterfeit packs.

Danish Medicines Agency

6-4-2017

More batches of EpiPen® are withdrawn

More batches of EpiPen® are withdrawn

MEDA has decided to withdraw four more batches of EpiPen®. The withdrawal concerns two batches of EpiPen® 300 micrograms/dose and two batches of EpiPen® Jr 150 micrograms/dose. The latter is used for acute hypersensitivity reactions in children. The reason for the withdrawal is that there is a risk that the auto-injector does not work.

Danish Medicines Agency

27-6-2018

EU/3/15/1590 (Merck Europe B.V.)

EU/3/15/1590 (Merck Europe B.V.)

EU/3/15/1590 (Active substance: Recombinant human monoclonal IgG1 antibody against programmed death ligand-1) - Transfer of orphan designation - Commission Decision (2018)4088 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/150/15/T/02

Europe -DG Health and Food Safety

21-3-2018

EU/3/16/1763 (IQVIA RDS Ireland Limited)

EU/3/16/1763 (IQVIA RDS Ireland Limited)

EU/3/16/1763 (Active substance: Tadekinig alfa) - Transfer of orphan designation - Commission Decision (2018)1825 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/150/16/T/01

Europe -DG Health and Food Safety